Sign in

    Athena • TD Cowen

    Athena is an Equity Research Analyst at TD Cowen, specializing in sector research with a focus on identifying high-impact trends and investment insights. She covers a portfolio of notable publicly traded companies, leveraging sophisticated analytics to deliver actionable recommendations to institutional clients. With a career rooted in rigorous financial analysis and a track record of delivering strong performance metrics recognized by investment research platforms, Athena brings substantial expertise and value to her coverage areas. She holds relevant Series securities licenses and maintains active professional registrations aligning with industry best practices.

    Athena's questions to SAGE Therapeutics Inc (SAGE) leadership

    Athena's questions to SAGE Therapeutics Inc (SAGE) leadership • Q3 2024

    Question

    An analyst named Athena, on for Ritu Baral, asked about the timeline for unveiling new early-stage assets and whether their focus would remain on neuropsychiatry.

    Answer

    Chief Medical Officer Laura Gault stated that a full portfolio prioritization process is currently underway and more details will be shared upon its completion. Chief Scientific Officer Mike Quirk added that research is focused on how endogenous steroids engage neurocircuits, extending beyond the established GABA and NMDA receptor pathways.

    Ask Fintool Equity Research AI